A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

Inclusion Criteria

• •1. Male or female aged \>18 years at the time of the Screening Visit.
• •2. Completion of study 4975-MN-202.
• •3. Female not of childbearing potential, defined as post-menopausal for at least 1 year, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or practicing one of the following medically acceptable methods of birth control throughout the study period:
• •1. Hormonal methods such as oral, implantable, injectable, or transdermal contraceptives for a minimum of 1 full cycle (based on the subject's usual menstrual cycle period) before investigational product (IP) administration.
• •2. Total abstinence from sexual intercourse since the last menses before IP administration.
• •3. Intrauterine device.
• •4. Double barrier method (condoms, sponge, diaphragm, with spermicidal jellies or cream).
• •4. Willing and able to understand the study requirements, abide by the study restrictions, complete the study procedures, pain scales, and weekly IWRS/IVRS entries, and to communicate meaningfully with the study personnel.
• •5. Signed an Informed Consent Form approved by the Institutional Review Board.
• •6. Subject agrees to take only the rescue medications for neuroma foot pain from the time of screening through study completion, and agrees to discontinue all topical medications for neuroma pain after Screening.